Lipid compound and use thereof in preparation of lipid nanoparticles

By preparing lipid nanoparticles with specific structures, the problem of insufficient drug delivery of fatty acid derivatives at the intramuscular injection site was solved, achieving efficient muscle targeting and drug expression, which is suitable for nucleic acid delivery.

WO2026233429A1PCT designated stage Publication Date: 2026-11-12HUZHOU VAKERNA BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/095655
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

The application of existing fatty acid derivatives in RNA recombination delivery has not been reported, and there is a lack of effective drug delivery methods, especially in terms of targeting and expression levels at the intramuscular injection site.

Method used

Lipid nanoparticles are prepared using lipid compounds with specific structures, including lipid moieties and linker moieties, for local injection to improve drug targeting and expression levels at the intramuscular injection site.

Benefits of technology

It significantly increased the expression level of the drug at the intramuscular injection site, which was superior to the expression level in the liver, and had a good muscle targeting effect, making it suitable for delivering nucleic acid payloads such as mRNA.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026095655_12112026_PF_FP_ABST
    Figure CN2026095655_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a lipid compound and a use thereof in the preparation of lipid nanoparticles.
Need to check novelty before this filing date? Find Prior Art

Description

A lipid compound and its application in the preparation of lipid nanoparticles

[0001] This application claims priority to the following prior patent applications:

[0002] The applicant filed an earlier application with the China National Intellectual Property Administration on May 9, 2025, with patent application number 202510600648.0 and titled "A lipid compound and its application in the preparation of lipid nanoparticles".

[0003] The full text of the aforementioned prior patent applications is incorporated herein by reference. Technical Field

[0004] This invention relates to the field of medicinal chemistry, and more particularly to a lipid compound and its application in the preparation of lipid nanoparticles. Background Technology

[0005] Fatty acid derivatives have a wide range of applications, including as surfactants, food additives, liposomes, and pharmaceutical compositions. The fatty acid derivatives containing disulfide structures of the compounds of this invention have the most important application in RNA recombination, and their structure and uses have not been previously reported. These compounds have great development potential. Summary of the Invention

[0006] This invention first provides a lipid molecule represented by Formula I:

[0007] Among them, LP1 and LP2 are lipid fractions;

[0008] In a specific embodiment of the present invention, the lipid portion is independently selected from C 6-30 Alkyl, C 6-30 alkenyl or C 6-30 The alkynyl group, optionally substituted by 1, 2, 3, 4 or 5 substituents selected from: -OH, halogen, cyano, C 1-30 Alkyl, C 1-30 Halogenated alkyl groups, -OC 1-30 Alkyl, -SC 1-30 Alkyl, amino, -NH-C 1-30 Alkyl and -N(C) 1-30Alkyl group 2; In another specific embodiment of the invention, the lipid portion is selected from or derived from steroid residues (such as cholesterol, sitosterol, codostrol, lycopene, campesterol, ergosterol, tomatine, ursolic acid, α-tocopherol, stigmasterol, alfalfa sterol, ergocalciferol, or campesterol), fat-soluble vitamin residues (such as vitamin D, vitamin E, vitamin K, vitamin A), or folic acid; preferably, at least one of LP1 or LP2 is selected from or derived from a fat-soluble vitamin residue, and the other is selected from C 12-22 Straight-chain or branched aliphatic hydrocarbon groups (alkyl, alkenyl or ynyl, preferably alkyl or alkenyl); preferably, LP1 and LP2 are each independently selected from C 12-22 A straight-chain or branched aliphatic hydrocarbon group (alkyl, alkenyl, or ynyl, preferably alkyl or alkenyl); wherein L1 and L2 are connecting portions, which are independently selected from bonds, -O-, -S-, -P-, -O-(HO-P=O)-O-, -N(RO)-, -CO-, -C(O)O-, -OC(O)-, -C(O)NH-, -NHC(O)-, -NHC(O)-NH-, optionally C substituted with one or more RO groups. 1-10 Alkylene, C 1-10 imidene group, C 1-10 The group is selected independently from the following: alkynyl group, 3-10 membered heterocyclic group optionally substituted with one or more R0 groups, or any combination thereof; more preferably, the group is selected independently from the following: -O-, -S-, -P-, -O-(HO-P=O)-O-, -N(R0)-, -CO-, C- group optionally substituted with one or more R0 groups. 1-10 Alkylene (e.g., C10) 1-6 Alkylene or C 1-4 Alkylene groups, optionally substituted with one or more R0 groups, are 3-10 membered heterocyclic groups (preferably 5-7 membered heterocyclic groups, wherein the heterocycle is O, S, or N, and contains at least one N atom) or any combination thereof. According to embodiments of the invention, each R0 may be the same or different, and is independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, C... 1-10 Alkyl, C 1-10 Alkoxy, halogenated C 1-10 Alkyl, Halogenated C 1-10 Alkyl groups; preferably, each R0 may be the same or different, and is independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkyl groups; more preferably, they are the same or different, and are independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated C 1-4 Alkyl, Halogenated C1-4 Alkoxy; preferably, L2 contains at least one nitrogen-containing heterocyclic alkyl group;

[0009] The linking groups (linking portions, "—") are optionally linked or interrupted by functional groups selected from -O-, -C(O)O-, -SC(O)O-, and -OC(O)NR. a -、-NR a C(O)NR a -、-OC(O)S-、-OC(O)O-、-NR a C(O)O-, -C(O)S-, -C(O)NR a -、-NR a C(O)S-、-SC(O)NR a -、-C(S)O-、-OC(S)NR a -、-NR a C(S)O- or click chemical groups such as triazole groups, said R a Selected from H or methyl;

[0010] Preferably, the connecting part is C 1-10 Straight-chain or branched alkylene groups, piperazine subunits, piperidinium subunits, -(CH2) 1-10 CO-, -O(CH2) 1-10 -、-(CH2) 1-10 C(O)O-、-(CH2) 1-10 CONH-、-O(CH2) 1-10 CO-, -O(CH2) 1-10 C(O)O-、-O(CH2) 1-10 CONH-、-OCO(CH2) 1-10 C(O)O-、-NHCO(CH2) 1-10 C(O)O-、-(CH2) 1-10 OC(O)(CH2) 1-10 CO- or combinations of the above groups; wherein the range 1-10 includes all point values ​​(1, 2, 3, 4, 5, 6, 7, 8, 9, 10) and combinations (such as 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, 4-5, 4-6, 4-7, 4-8, 4-9, 4-10, 5-6, 5-7, 5-8, 5-9, 5-10, 6-7, 6-8, 6-9, 6-10, 7-8, 7-9, 7-10, 8-9, 8-10 or 9-10).

[0011] Preferably, the connecting portion is selected from -(C(G)2). a -, a is an integer selected from 1 to 16, where one or more of -C(G)2- can be independently and optionally replaced by -O-, -S-, -C(O)-, -C(S)-, -S(O)-, -S(O)2-, -SS-, -N(G)C(O)-, -C(O)N(G)-, -N(G)-, Or a 3-10 membered heterocyclic group (preferably a 5-7 membered heterocyclic group, wherein the hetero is O, S or N, and contains at least one N atom);

[0012] Wherein, each occurrence of G is independently selected from hydrogen, deuterium, halogen, hydroxyl, amino, C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl, or C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl, or C3-10 cycloalkyl that is optionally substituted by one or more of deuterium, halogen, hydroxyl, and amino.

[0013] Where n4 is selected from integers from 0 to 4, such as 0, 1, 2, 3 or 4, preferably 0;

[0014] Where n5 is selected from integers from 0 to 4, such as 0, 1, 2, 3 or 4, preferably 1;

[0015] Where n6 is an integer from 1 to 5, such as 1, 2, 3, 4 or 5, preferably 1.

[0016] In a further embodiment of the present invention, the compound of formula I is formula I-1:

[0017] in:

[0018] L 2’ L3 and L3 are the linking groups defined above;

[0019] Preferably, L 2’ C 1-6 Alkyl group, L3 is C 1-12 Alkyl group, -(CH2) 1-6 O(CH2) 1-6 O-, -(CH2) 1-6 O(CH2) 1-6 C(O)O-、-(CH2) 1-6 OC(O)(CH2) 1-6 C(O)O-、-(CH2) 1-6 OC(O)(CH2) 1-6 C(O)- or -(CH2) 1-6 OC(O)(CH2) 1-6 O-;

[0020] G1 and G2 are either N or CH, and at least one of them is N; preferably, G1 is N and G2 is CH.

[0021] G3-G6 can be either N or CH;

[0022] n6 is an integer from 1 to 5, such as 1, 2, 3, 4 or 5;

[0023] m1 and m2 are integers from 0 to 2, such as 0, 1, or 2; preferably, one of m1 and m2 is 0 and the other is 1, or both m1 and m2 are 1, or one of m1 and m2 is 1 and the other is 2.

[0024] Preferably, LP1 or LP2 is independently selected from fatty alcohol groups, fatty amine groups, fatty acid groups, or alcohol (ether) or amino (amide) groups derived from fatty acids. Examples of saturated fatty acids include caprylic acid (C8), capric acid (C10), lauric acid (C12), myristic acid (C14), palmitic acid (C16), stearic acid (C18), arachidic acid (C20), or docosuccinic acid, etc.; examples of unsaturated fatty acids include monounsaturated fatty acids such as myristoleic acid (C14). 14:1, cis-9), palmitoleic acid (C16:1, cis-9), oleic acid (C18:1, cis-9), trans oleic acid (C18:1, trans-9), ricinoleic acid (C18:1, cis-9), etc., or polyunsaturated fatty acids such as linolenic acid, DHA and EPA, etc.; the alcohol (ether) groups derived therefrom refer to alcohol (or ether) groups with the same number of carbon atoms obtained by reducing the carboxyl group of the fatty acid, for example, lauryl alcohol corresponds to the reduction of lauric acid (C12).

[0025] Preferably, LP1 or LP2 is independently selected from α, β, γ and δ-tocopherols or α, β, γ and δ-tocotrienols or mixtures thereof.

[0026] In a further embodiment of the present invention, the compound of formula I is formula I-1':

[0027] in:

[0028] L1, L 2’ L3 and L3 are the linking groups defined above;

[0029] LP1 or LP2 are the lipid fractions defined above;

[0030] n4 is selected from integers from 0 to 4, such as 0, 1, 2, 3 or 4, preferably 0;

[0031] n5 is selected from integers from 0 to 4, such as 0, 1, 2, 3 or 4, preferably 1;

[0032] n6 is an integer from 1 to 5, such as 1, 2, 3, 4 or 5, preferably 1;

[0033] G1 and G2 are either N or CH, and at least one of them is N; preferably, G1 is N and G2 is CH.

[0034] G3, G4, G5, and G6 are either N or CH;

[0035] m1 and m2 are integers from 0 to 2, such as 0, 1, or 2; preferably, one of m1 and m2 is 0 and the other is 1, or both m1 and m2 are 1, or one of m1 and m2 is 1 and the other is 2;

[0036] Preferably, L1 is C 1-12 Alkylene, -(CH2) 1-10 O-, -(CH2) 1-10 C(O)-、-(CH2) 1-10 C(O)O- (e.g., -(CH2)5O-, -(CH2)5C(O)O-);

[0037] Preferably, L 2’ C 1-12 Alkylene; more preferably C 1-6 Alkylene (e.g., C2 alkylene);

[0038] Preferably, L3 is C 1-12 Alkylene, -(CH2) 1-6 O(CH2) 1-6 O-, -(CH2) 1-6 O(CH2) 1-6 C(O)O-、-(CH2) 1-6 OC(O)(CH2) 1-6 C(O)O-、-(CH2) 1-6 OC(O)(CH2) 1-6 C(O)-、-(CH2) 1-6 OC(O)(CH2) 1-6 -or-(CH2) 1-6 OC(O)(CH2) 1-6 O-; further preferably -(CH2)2OC(O)(CH2)3C(O)O-, -(CH2)2OC(O)(CH2)3C(O)-, -(CH2)2OC(O)(CH2)3-);

[0039] Preferably, LP1 or LP2 is independently selected from C 6-30 Alkyl, C 6-30 alkenyl or C 6-30Alkyne, or selected from or derived from steroid residues (such as cholesterol, sitosterol, codostrol, lycopene, campesterol, ergosterol, tomatine, ursolic acid, α-tocopherol, stigmasterol, alfalfa sterol, ergocalciferol or campesterol), fat-soluble vitamin residues (such as vitamin D, vitamin E, vitamin K, vitamin A) or folic acid;

[0040] Preferably, LP1 or LP2 is independently selected from: -CHR'R"; wherein R' and R" are the same or different, and are independently selected from C 2-12 Straight-chain aliphatic hydrocarbon groups or C 2-12 Branched aliphatic hydrocarbon groups; more preferably, R' and R'' may be the same or different, and are independently selected from C. 2-12 Or C 3-11 Or C 4-10 Or C 5-9 Or C 6-8 Or C7 straight-chain alkyl, C 2-12 Or C 3-11 Or C 4-10 Or C 5-9 Or C 6-8 Or C7 branched alkyl, C 2-12 Or C 3-11 Or C 4-10 Or C 5-9 Or C 6-8 Or C7 straight-chain alkenyl, C 2-12 Or C 3-11 Or C 4-10 Or C 5-9 Or C 6-8 Or C7 branched alkenyl groups. Exemplarily, LP1 or LP2 is independently selected from:

[0041] Preferably, LP1 or LP2 is independently selected from:

[0042] Preferably, LP1 or LP2 is independently selected from or derived from fat-soluble vitamin residues, C 12-22 Straight-chain or branched aliphatic hydrocarbon groups (alkyl, alkenyl or ynyl, preferably alkyl or alkenyl);

[0043] Preferably, LP1 is selected from C 12-22 The linear or branched aliphatic hydrocarbon group (alkyl, alkenyl, or ynyl, preferably alkyl or alkenyl); preferably, LP2 is selected from or derived from fat-soluble vitamin residues, C 12-22 Straight-chain or branched aliphatic hydrocarbon groups (alkyl, alkenyl or ynyl, preferably alkyl or alkenyl);

[0044] Preferably, the fat-soluble vitamin residues are:

[0045] Among them, G7, G8, or G9 is H or methyl. It can be a single bond or a double bond. In a further embodiment of the present invention, the compound of formula I is formula I-1”:

[0046] Preferred options are:

[0047] Wherein, G2 is N or CH;

[0048] L3 is -OC(O)(CH2) 1-9 C(O)-、-C(O)(CH2) 1-9 C(O)-、-(CH2) 1-9 C(O)-、-(CH2) 1-9 OC(O)- or -(CH2) 1-6 OC(O)(CH2) 1-6 C(O)-;

[0049] LP1 and LP2 have the above definitions;

[0050] Preferably, LP1 or LP2 is independently selected from C 6-30 Alkyl, C 6-30 Alkenyl groups, or those selected from or derived from fat-soluble vitamin residues (such as vitamin D, vitamin E, vitamin K, and vitamin A);

[0051] Preferably, LP1 or LP2 is independently selected from or derived from fat-soluble vitamin residues, C 12-22 Straight-chain or branched aliphatic hydrocarbon groups (alkyl, alkenyl or ynyl, preferably alkyl or alkenyl);

[0052] Preferably, LP1 is selected from C 12-22 The linear or branched aliphatic hydrocarbon group (alkyl, alkenyl, or ynyl, preferably alkyl or alkenyl); preferably, LP2 is selected from or derived from fat-soluble vitamin residues, C 12-22 Straight-chain or branched aliphatic hydrocarbon groups (alkyl, alkenyl or ynyl, preferably alkyl or alkenyl).

[0053] In a further embodiment of the present invention, the compound of formula I is formula I-2:

[0054] Where G7, G8, or G9 is H or methyl. It can be a single or double bond; L3 is -OC(O)(CH2). 1-9 C(O)-、-C(O)(CH2) 1-9 C(O)-、-(CH2) 1-9 C(O)-、-(CH2) 1-9OC(O)- or -(CH2) 1-6 OC(O)(CH2) 1-6 C(O)-.

[0055] In a further embodiment of the present invention, the compound of formula I is formula I-3:

[0056] A further preferred embodiment is:

[0057] Among them, G3, G4, or G5 are H or methyl, or G7, G8, or G9 are H or methyl. It is a single bond or a double bond. More preferably, it is a compound containing:

[0058] In a further embodiment of the present invention, the compound of formula I is formula I-5 or formula I-6:

[0059] Where n1 is 1 to 6, n2 and n3 are 1 to 3, n4 is 1 to 3, and n7 is 1 to 6;

[0060] L3, LP1, and LP2 have the same definition as described above.

[0061] In a further embodiment of the present invention, the compound of formula I is the compound shown in formula I-8:

[0062] Among them, L3, LP1, and LP2 have the above definitions; G2 is CH or N.

[0063] More preferably, it is (Equation I-7):

[0064] Among them, n4-n6, as well as LP1 and LP2, have the same meaning as described above.

[0065] According to an embodiment of the present invention, in formulas I-8 and I-7, n4 is selected from natural numbers 0-5, n5 is selected from natural numbers 1-5, and n6 is selected from natural numbers 1-5; preferably, n4 is selected from 0, 1, or 2, n5 is selected from 1 or 2, and n6 is selected from 1 or 2.

[0066] According to an embodiment of the present invention, in formulas I-8 and I-7, LP1 is selected from C. 12-22 A straight-chain or branched aliphatic hydrocarbon group (alkyl, alkenyl, or ynyl, preferably alkyl or alkenyl); preferably, LP1 is selected from C 12-22 Straight-chain aliphatic hydrocarbon groups or C 12-22 Branched aliphatic hydrocarbon groups; more preferably, LP1 is selected from C 12-22straight-chain alkyl, C 12-18 straight-chain alkyl, C 12-22 straight-chain alkenyl, C 12-18 straight-chain alkenyl, C 12-22 Branched alkyl, C 12-18 Branched alkyl groups, C 12-22 Branched alkenyl, C 12-18 Branched alkenyl groups; exemplarily, LP1 is selected from...

[0067] According to embodiments of the present invention, in formulas I-8 and I-7, LP2 is selected from or derived from fat-soluble vitamin residues, C 12-22 The linear or branched aliphatic hydrocarbon group (alkyl, alkenyl, or ynyl, preferably alkyl or alkenyl); preferably, LP2 is selected from or derived from fat-soluble vitamin residues, C 12-22 Straight-chain aliphatic hydrocarbon groups or C 12-22 Branched aliphatic hydrocarbon groups; preferably, LP2 is selected from or derived from fat-soluble vitamin residues, C 12-22 straight-chain alkyl, C 12-18 straight-chain alkyl, C 12-22 straight-chain alkenyl, C 12-18 straight-chain alkenyl, C 12-22 Branched alkyl, C 12-18 Branched alkyl groups, C 12-22 Branched alkenyl, C 12-18 Branched alkenyl groups; exemplarily, LP1 is selected from... (trans-9-octadecenyl).

[0068] In a further embodiment of the present invention, the compound of formula I is selected from the following compounds:

[0069] In a further embodiment of the present invention, the compound of formula I is selected from compounds T(A+B), T1-T21 in the specification.

[0070] The present invention provides lipid nanoparticles for local injection, comprising the ionizable lipid compound described herein, wherein the lipid nanoparticles are capable of functioning at the injection site.

[0071] In a preferred embodiment, the lipid nanoparticles further comprise neutral lipids, structural lipids, and polymeric lipids.

[0072] In a preferred embodiment, the site of local injection is muscle or tumor tissue, preferably muscle.

[0073] In another aspect, the present invention provides a lipid nanoparticle composition comprising any of the lipid nanoparticles described above and a loading.

[0074] In another aspect, the present invention provides a method for preparing the above-described lipid nanoparticle composition, comprising: mixing the various lipid components and then mixing them with a loading.

[0075] In another aspect, the present invention provides a pharmaceutical composition comprising any of the lipid nanoparticle compositions described above, and pharmaceutically acceptable excipients.

[0076] In another aspect, the present invention provides the use of any of the above-described lipid nanoparticle compositions, or the above-described pharmaceutical compositions, in the preparation of medicaments for treating, diagnosing, or preventing diseases.

[0077] In another aspect, the present invention provides the use of any of the above-described lipid nanoparticle compositions, or the above-described pharmaceutical compositions, in the preparation of a medicament for delivery of a payload, said payload being selected from one or more therapeutic agents, preventative agents, or diagnostic agents.

[0078] In another aspect, the present invention provides a method for treating, diagnosing, or preventing a disease in a subject, comprising administering to the subject any of the lipid nanoparticle compositions described above, or the pharmaceutical compositions described above.

[0079] In another aspect, the present invention provides any of the above-described lipid nanoparticle compositions, or the above-described pharmaceutical compositions, for the treatment, diagnosis, or prevention of diseases.

[0080] In another aspect, the present invention provides a method for delivering a payload into a subject, comprising administering to the subject any of the lipid nanoparticle compositions described above, or the pharmaceutical compositions described above.

[0081] In another aspect, the present invention provides any of the above-described lipid nanoparticle compositions, or the above-described pharmaceutical compositions, for delivering a payload.

[0082] In a specific implementation, the load is selected from one or more of a therapeutic agent, a preventive agent, or a diagnostic agent; preferably, the therapeutic agent, preventive agent, or diagnostic agent is a nucleic acid.

[0083] In a more specific embodiment, the nucleic acid is selected from one or more of ASO, RNA, or DNA.

[0084] In a more specific embodiment, the RNA is selected from one or more of interfering RNA (RNAi), small interfering RNA (siRNA), short hairpin RNA (shRNA), antisense RNA (aRNA), messenger RNA (mRNA), modified messenger RNA (mmRNA), long noncoding RNA (lncRNA), microRNA (miRNA), small activating RNA (saRNA), polymeric coding nucleic acid (MCNA), polymeric coding nucleic acid (PCNA), guide RNA (gRNA), CRISPR RNA (crRNA), or ribozymes, preferably mRNA, more preferably modified mRNA.

[0085] Beneficial technical effects

[0086] The lipid molecule formulation based on this invention has good muscle-targeting effect, and the expression level of the drug in the injection site is significantly higher than that in the liver, which is expected to be applied to targeted intramuscular injection formulations. Attached Figure Description

[0087] Figure 1: Compound A2 1 H NMR spectrum.

[0088] Figures 2a and 2b: Compound A3 1 H NMR spectrum and mass spectrum.

[0089] Figures 3a and 3b: Compound A6 1 H NMR spectrum and mass spectrum.

[0090] Figures 4a and 4b: Partial heterocyclic intermediate of compound B 1 H NMR spectrum and mass spectrum.

[0091] Figures 5a and 5b: Trts intermediate of compound B 1 H NMR spectrum and mass spectrum.

[0092] Figures 6a and 6b: Partial disulfide intermediate of compound B 1 H NMR spectrum and mass spectrum.

[0093] Figures 7a and 7b: Compound T 1 H NMR spectrum and mass spectrum.

[0094] Figure 8: Particle size test results of control compound SM-102 and test compounds T1-T21.

[0095] Figure 9: Homogeneity test results of control compound SM-102 and test compounds T1-T21.

[0096] Figure 10: Surface potential test results of control compound SM-102 and test compounds T1-T21.

[0097] Figure 11: Encapsulation efficiency test results of control compound SM-102 and test compounds T1-T21.

[0098] Figure 12: Delivery efficiency test results of control compound SM-102 and test compounds T1-T21.

[0099] Figure 13: Results of in situ expression ratio test of control compound SM-102 and test compounds T1-T21.

[0100] Figure 14: Changes in peripheral blood alanine aminotransferase levels 8 hours after primary and booster immunizations of SM102 and the LNP formulations of the compounds of this invention compared to pre-immunization levels.

[0101] Figure 15: Levels of pro-inflammatory factors in the liver 8 hours after booster immunization with SM102 and LNP formulations of the compounds of this invention.

[0102] Figure 16: COVID-19 vaccine trial schedule.

[0103] Figure 17: RBD-specific IgG levels in peripheral blood 14 days after primary and booster immunization with SM102 and the LNP formulation of the compounds of this invention.

[0104] Figure 18: RBD-specific cellular immunity levels / cytokines in spleen 28 days after COVID-19 vaccine booster immunization with LNP formulations of SM102 and the compounds of this invention.

[0105] Figure 19: The protective effect of SM102 and the LNP formulation of the compound of the present invention on mice 21 days after booster immunization, and the detection of pathological damage in the lungs.

[0106] Figure 20: The protective effect of SM102 and the LNP formulation of the compound of the present invention on mice 21 days after booster immunization, with detection of viral titer in the lungs.

[0107] Figure 21: G protein-specific IgG levels in peripheral blood 14 days after primary and booster immunizations of subunit vaccines and LNP formulations of the compounds of this invention.

[0108] Figure 22: Neutralizing antibody levels in peripheral blood 14 days after booster immunization for subunit vaccines and LNP formulations of the compounds of this invention. Detailed Implementation

[0109] Chemical definition

[0110] The definitions of specific functional groups and chemical terms are described in more detail below.

[0111] The term "oxo-substituent" refers to a double bond formed when two hydrogen atoms at the same substitution position are replaced by the same oxygen atom.

[0112] When listing a range of values, it is assumed that each value and the subranges within that range are included. For example, "C 1-6 Alkyl groups include C1, C2, C3, C4, C5, C6, and C6. 1-6 C 1-5 C 1-4 C 1-3 C 1-2 C 2-6 C 2-5 C 2-4 C 2-3 C 3-6 C 3-5 C 3-4 C 4-6 C 4-5 and C 5-6 alkyl.

[0113] "alkyl" refers to a straight-chain or branched saturated hydrocarbon group having the corresponding carbon atom, such as C. 6-30 Alkyl groups are straight-chain or branched alkyl groups having 6 to 30 carbon atoms.

[0114] "Alkenyl" refers to a straight-chain or branched hydrocarbon group having a corresponding carbon atom and at least one carbon-carbon double bond, such as C 6-30 Alkenyl refers to a straight-chain or branched hydrocarbon group having 6-30 carbon atoms and at least one carbon-carbon double bond.

[0115] "Alkyne" refers to a straight-chain or branched hydrocarbon group having a corresponding carbon atom and at least one carbon-carbon triple bond and optionally one or more carbon-carbon double bonds, such as C 6-30An alkynyl group refers to a straight-chain or branched hydrocarbon group having a carbon atom and at least one carbon-carbon triple bond and optionally one or more carbon-carbon double bonds. Aliphatic hydrocarbon groups having 12-22 carbon atoms can be straight-chain or branched, preferably straight-chain. Aliphatic hydrocarbon groups can be saturated or unsaturated. In the case of unsaturated aliphatic hydrocarbon groups, the aliphatic hydrocarbon group typically contains 1-6, preferably 1-3, more preferably 1-2 unsaturated bonds. When the unsaturated bonds include carbon-carbon double bonds and carbon-carbon triple bonds, carbon-carbon double bonds are preferred. Aliphatic hydrocarbon groups preferably have 12-18, most preferably 13-17 carbon atoms. Although aliphatic hydrocarbon groups include alkyl, alkenyl, alkynyl, etc., they are preferably alkyl or alkenyl. Specific examples of aliphatic hydrocarbon groups having 12-22 carbon atoms include dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecanyl, octadecyl, nonadecanyl, eicosyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecanyl, octadecyl, nonadecanyl, eicosyl, dodecyl, decadecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecanyl, octadecyl, octadecyl, nonadecanyl, eicosyl, dodec ... The aliphatic hydrocarbon group having 12-22 carbon atoms is preferably tridecyl, tetradecyl, heptadecanyl, octadecyl, heptadecanyl or octadecadecanyl, and is particularly preferred to be tridecyl, heptadecanyl or heptadecanyl.

[0116] “C 1-6 "Alkyl" refers to a straight-chain or branched saturated hydrocarbon group having 1 to 6 carbon atoms. In some embodiments, C 1-4 Alkyl and C 1-2 Alkyl groups are preferred. C 1-6 Examples of alkyl groups include: methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentyl (C5), pentyl (C5), neopentyl (C5), 3-methyl-2-butyl (C5), tert-pentyl (C5), and n-hexyl (C6). The term "C" is used in conjunction with the preceding text. 1-6"Alkyl" also includes heteroalkyl, wherein one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). The alkyl group may be optionally substituted by one or more substituents, for example, by 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. Common alkyl abbreviations include: Me(-CH3), Et(-CH2CH3), iPr(-CH(CH3)2), nPr(-CH2CH2CH3), n-Bu(-CH2CH2CH2CH3) or i-Bu(-CH2CH(CH3)2).

[0117] “C 2-6 "Alkenyl" refers to a straight-chain or branched hydrocarbon group having 2 to 6 carbon atoms and at least one carbon-carbon double bond. In some embodiments, C 2-4 Alkenyl groups are preferred. C 2-6 Examples of alkenyl groups include: vinyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), pentenyl (C5), pentadienyl (C5), hexenyl (C6), and so on. The term "C" is used in conjunction with these groups. 2-6 "Alkenyl" also includes heteroalkenyl groups, wherein one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). The alkenyl group may be optionally substituted by one or more substituents, for example, by 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0118] “C 2-6 "Alkyne" refers to a straight-chain or branched hydrocarbon group having 2 to 6 carbon atoms, at least one carbon-carbon triple bond, and optionally one or more carbon-carbon double bonds. In some embodiments, C 2-4 The alkynyl group is preferred. C 2-6 Examples of alkynyl groups include, but are not limited to: ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), pentyynyl (C5), hexynyl (C6), etc. The term "C" is used in conjunction with other alkynyl groups. 2-6 "Alkyne" also includes heteroyne, wherein one or more (e.g., 1, 2, 3 or 4) carbon atoms are replaced by heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). The alkynyl group may be optionally substituted by one or more substituents, for example, by 1 to 5 substituents, 1 to 3 substituents or 1 substituent.

[0119] “C 1-6 "Alkylene" refers to the removal of C 1-6 The alkyl group is a divalent group formed by another hydrogen atom, and can be substituted or unsubstituted. In some embodiments, C 1-4 Alkylene, C 2-4Alkylene and C 1-3 Alkylenes are preferred. Unsubstituted alkylenes include, but are not limited to: methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), butylene (-CH2CH2CH2CH2-), pentylene (-CH2CH2CH2CH2CH2-), hexylene (-CH2CH2CH2CH2CH2CH2-), and so on. Exemplary substituted alkylenes, for example, those substituted with one or more alkyl (methyl) groups, include, but are not limited to: substituted methylene (-CH(CH3)-, -C(CH3)2-), substituted ethylene (-CH(CH3)CH2-, -CH2CH(CH3)-, -C(CH3)2CH2-, -CH2C(CH3) 2- ), substituted propylidenes (-CH(CH3)CH2CH2-, -CH2CH(CH3)CH2-, -CH2CH2CH(CH3)-, -C(CH3)2CH2CH2-, -CH2C(CH3)2CH2-, -CH2CH2C(CH3)2-), etc.

[0120] “C 2-6 "Alkenyl" refers to the group that has been de-carbonied. 2-6 The other hydrogen atom of the alkenyl group forms a divalent group, which can be substituted or unsubstituted. In some embodiments, C 2-4 Alkenyl groups are particularly preferred. Exemplary unsubstituted alkenyl groups include, but are not limited to, vinylidene (-CH=CH-) and propenylidene (e.g., -CH=CHCH2-, -CH2-CH=CH-). Exemplary substituted alkenyl groups, such as alkenyl groups substituted with one or more alkyl (methyl) groups, include, but are not limited to, substituted ethylidene (-C(CH3)=CH-, -CH=C(CH3)-), substituted propenylidene (-C(CH3)=CHCH2-, -CH=C(CH3)CH2-, -CH=CHCH(CH3)-, -CH=CHC(CH3)2-, -CH(CH3)-CH=CH-, -C(CH3)2-CH=CH-, -CH2-C(CH3)=CH-, -CH2-CH=C(CH3)-), etc.

[0121] “C 2-6 "Iso-ynyl group" refers to the group with the C group removed. 2-6 The other hydrogen atom of the alkynyl group forms a divalent group, which can be substituted or unsubstituted. In some embodiments, C 2-4 The ethynyl group is particularly preferred. Exemplary ethynyl groups include, but are not limited to: ethynyl group (-C≡C-), substituted or unsubstituted propynyl group (-C≡CCH2-), etc.

[0122] “C 0-6 "alkylene" refers to chemical bonds and the aforementioned "C" 1-6 Alkylene", "C" 0-4 "alkylene" refers to chemical bonds and the aforementioned "C" 1-4 Alkylene".

[0123] "Halogen" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), and iodine (I).

[0124] Therefore, "C" 1-6 "Halogenated alkyl" refers to the above "C 1-6 "alkyl" is substituted with one or more halogen groups. In some embodiments, C 1-4 Halogenated alkyl groups are particularly preferred, and C4 groups are more preferred. 1-2 Halogenated alkyl groups. Exemplary alkyl halogenated groups include, but are not limited to: -CF3, -CH2F, -CHF2, -CHFCH2F, -CH2CHF2, -CF2CF3, -CCl3, -CH2Cl, -CHCl2, 2,2,2-trifluoro-1,1-dimethyl-ethyl, etc. The alkyl halogenated group can be substituted at any available connection point, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0125] “C 3-10 "Cycloalkyl" refers to a non-aromatic cyclic hydrocarbon group having 3 to 10 cyclic carbon atoms and zero heteroatoms, optionally containing 1, 2, or 3 double or triple bonds. In some embodiments, C 5-10 cycloalkyl, C 3-7 cycloalkyl and C 3-6 Cycloalkyl groups are particularly preferred, and C10 is more preferred. 5-7 cycloalkyl and C 5-6Cycloalkyl groups. Cycloalkyl groups also include ring systems in which the aforementioned cycloalkyl ring is fused with one or more aryl or heteroaryl groups, wherein the bonding point is on the cycloalkyl ring, and in such cases, the number of carbons continues to represent the number of carbons in the cycloalkyl system. Cycloalkyl groups also include the aforementioned cycloalkyl ring in which substituents on any non-adjacent carbon atoms are linked to form a bridged ring, together forming a polycyclic alkane sharing two or more carbon atoms. Cycloalkyl groups also include the aforementioned cycloalkyl ring in which substituents on the same carbon atom are linked to form a ring, together forming a polycyclic alkane sharing one carbon atom. Exemplary cycloalkyl groups include, but are not limited to: cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cyclohepttrienyl (C7), etc. The cycloalkyl group may be optionally substituted by one or more substituents, for example, by 1 to 5 substituents, 1 to 3 substituents or 1 substituent.

[0126] “C 3-10 "Cycloalkylene" refers to the alkylene group after removing C24. 3-10 The cycloalkyl group is a divalent group formed by another hydrogen atom, and can be substituted or unsubstituted. In some embodiments, C 3-6 Cycloalkylene and C 3-4 Cycloalkylene compounds are particularly preferred, especially cyclopropylene compounds.

[0127] "3-10 membered heterocyclic groups" refer to saturated or unsaturated groups of 3- to 10 membered non-aromatic ring systems having a ring carbon atom and 1 to 5 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon, and optionally contains 1, 2, or 3 double or triple bonds. In heterocyclic groups containing one or more nitrogen atoms, the bonding point can be a carbon or nitrogen atom, provided the valence allows. In some embodiments, a 5-10 membered heterocyclic group is preferred, which is a 5-10 membered non-aromatic ring system having a cyclic carbon atom and 1 to 5 cyclic heteroatoms; in some embodiments, a 3-7 membered heterocyclic group is preferred, which is a 3-7 membered non-aromatic ring system having a cyclic carbon atom and 1 to 4 cyclic heteroatoms; a 5-7 membered heterocyclic group is preferred, which is a 5-7 membered non-aromatic ring system having a cyclic carbon atom and 1 to 3 cyclic heteroatoms; a 3-6 membered heterocyclic group is preferred, which is a 3-6 membered non-aromatic ring system having a cyclic carbon atom and 1 to 3 cyclic heteroatoms; a 4-6 membered heterocyclic group is preferred, which is a 4-6 membered non-aromatic ring system having a cyclic carbon atom and 1 to 3 cyclic heteroatoms; and a 5-6 membered heterocyclic group is preferred, which is a 5-6 membered non-aromatic ring system having a cyclic carbon atom and 1 to 3 cyclic heteroatoms. Heterocyclic groups also include ring systems in which the aforementioned heterocyclic ring is fused with one or more cycloalkyl groups, wherein the linking point is on the heterocyclic ring; or ring systems in which the aforementioned heterocyclic ring is fused with one or more aryl or heteroaryl groups, wherein the linking point is on the heterocyclic ring; and in such cases, the number of ring members continues to represent the number of ring members in the heterocyclic ring system. Heterocyclic groups also include the aforementioned heterocyclic ring in which substituents on any non-adjacent carbon or nitrogen atom are linked to form a bridged ring, together forming a polycyclic heteroalkane sharing two or more carbon or nitrogen atoms. Heterocyclic groups also include the aforementioned heterocyclic ring in which substituents on the same carbon atom are linked to form a ring, together forming a polycyclic heteroalkane sharing one carbon atom. Exemplary 3-membered heterocyclic groups containing one heteroatom include, but are not limited to: azirropropyl, oxetane, and thiorenyl. Exemplary 4-membered heterocyclic groups containing one heteroatom include, but are not limited to: azirrobutyl, oxetane, and thiorenyl. Exemplary 5-membered heterocyclic groups containing one heteroatom include, but are not limited to: tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolylyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to: pyrazolylyl, dioxasulfuranyl, oxasulfuranyl, disulfuranyl, and oxazolidinyl-2-one. Exemplary 5-membered heterocyclic groups containing three heteroatoms include, but are not limited to: triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclic groups containing one heteroatom include, but are not limited to: piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to: piperazinyl, morpholinyl, dithiohexane, and dioxane. Exemplary 6-membered heterocyclic groups containing three heteroatoms include, but are not limited to: triazinanyl. Exemplary 7-membered heterocyclic groups containing one heteroatom include, but are not limited to: azirheptanyl, oxeheptanyl, and thioheptanyl. Exemplary 5-membered heterocyclic groups fused to a C6 aryl ring (also referred to herein as 5,6-bicyclic heterocyclic groups) include, but are not limited to: dihydroindolyl, isodihydroindolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, benzoxazolinoneyl, etc. Exemplary 6-membered heterocyclic groups fused to a C6 aryl ring (also referred to herein as 6,6-bicyclic heterocyclic groups) include, but are not limited to: tetrahydroquinolinyl, tetrahydroisoquinolinyl, etc. Heterocyclic groups also include those that share one or two atoms with a cycloalkyl, heterocyclic, aryl, or heteroaryl group to form a bridged or spirocyclic ring, wherein the shared atom may be a carbon or nitrogen atom, provided the valence allows. Heterocyclic groups also include those that can be optionally substituted with one or more substituents, for example, by 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0128] "Alkoxy" refers to the oxyether form of a straight-chain or branched alkyl group, i.e., -O-alkyl. Similarly, "methoxy" refers to -O-CH3.

[0129] "Optionally replaced by..." means that it can be replaced by a specified substituent or it can be unsubstituted;

[0130] The divalent groups formed by removing one hydrogen atom from the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups defined above are collectively referred to as "subunits". Cyclic groups such as cycloalkyl, heterocyclic, aryl, and heteroaryl are collectively referred to as "cyclogroups".

[0131] The alkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl groups defined in this article are optional substituted groups.

[0132] Exemplary substituents on carbon atoms include, but are not limited to: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa -ON(R) bb )2、-N(R bb )2、-N(R bb )3 + X - -N(OR) cc )R bb -SH, -SR aa -SSR cc -C(=O)R aa -CO2H, -CHO, -C(OR)cc )2、-CO2R aa 、-OC(=O)R aa 、-OCO2R aa 、-C(=O)N(R bb )2、-OC(=O)N(R bb )2、-NR bb C(=O)R aa 、-NR bb CO2R aa 、-NR bb C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa 、-OC(=NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-OC(=NR bb )N(R bb )2、-NR bb C(=NR bb )N(R bb )2、-C(=O)NR bb SO2R aa 、-NR bb SO2R aa 、-SO2N(R bb )2、-SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa )3、-OSi(R aa )3、-C(=S)N(R bb )2、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa 、-P(=O)2R aa 、-OP(=O)2R aa 、-P(=O)(R aa)2、-OP(=O)(R aa )2、-OP(=O)(OR cc )2、-P(=O)2N(R bb )2、-OP(=O)2N(R bb )2、-P(=O)(NR bb )2、-OP(=O)(NR bb )2、-NR bb P(=O)(OR cc )2、-NR bb P(=O)(NR bb )2、-P(R cc )2、-P(R cc )3、-OP(R cc )2、-OP(R cc )3、-B(R aa 2. -B(OR) cc )2、-BR aa (OR cc ), alkyl, haloalkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl, wherein each alkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl is independently bounded by 0, 1, 2, 3, 4, or 5 R groups. dd Group substitution;

[0133] Or the two hydrogen-bearing groups on the carbon atom: =O, =S, =NN(R) bb )2、=NNR bb C(=O)R aa =NNR bb C(=O)OR aa =NNR bb S(=O)2R aa =NR bb or = NOR cc replace;

[0134] R aa Each of them is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl, or two R aa Groups are combined to form heterocyclic or heteroaryl rings, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl group is independently bounded by 0, 1, 2, 3, 4, or 5 R groups. dd Group substitution;

[0135] R bb Each is independently selected from: hydrogen, -OH, -OR aa -N(R) cc )2、-CN、-C(=O)R aa-C(=O)N(R) cc )2、-CO2R aa -SO2R aa -C(=NR) cc OR aa -C(=NR) cc )N(R cc )2、-SO2N(R cc )2、-SO2R cc -SO2OR cc -SOR aa -C(=S)N(R) cc )2、-C(=O)SR cc -C(=S)SR cc -P(=O)2R aa -P(=O)(R aa )2、-P(=O)2N(R cc )2、-P(=O)(NR cc 2. Alkyl, haloalkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl, or two R bb Groups are combined to form heterocyclic or heteroaryl rings, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl group is independently bounded by 0, 1, 2, 3, 4, or 5 R groups. dd Group substitution;

[0136] R cc Each is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl, or two R cc Groups are combined to form heterocyclic or heteroaryl rings, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl group is independently bounded by 0, 1, 2, 3, 4, or 5 R groups. dd Group substitution;

[0137] R dd Each is independently selected from: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee -ON(R) ff )2、-N(R ff )2,、-N(R ff )3 + X - -N(OR) ee )R ff -SH, -SR ee -SSR ee -C(=O)R ee -CO2H, -CO2R ee -OC(=O)Ree -OCO2R ee -C(=O)N(R) ff )2、-OC(=O)N(R ff )2、-NR ff C(=O)R ee -NR ff CO2R ee -NR ff C(=O)N(R ff )2、-C(=NR ff OR ee -OC(=NR) ff )R ee -OC(=NR) ff OR ee -C(=NR) ff )N(R ff )2、-OC(=NR ff )N(R ff )2、-NR ff C(=NR ff )N(R ff )2、-NR ff SO2R ee -SO2N(R) ff )2、-SO2R ee -SO2OR ee -OSO2R ee -S(=O)R ee 、-Si(R ee )3、-OSi(R ee 3. -C(=S)N(R) ff )2、-C(=O)SR ee -C(=S)SR ee -SC(=S)SR ee -P(=O)2R ee -P(=O)(R ee )2、-OP(=O)(R ee )2、-OP(=O)(OR ee 2. Alkyl, haloalkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, heteroaryl, wherein each alkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl group is independently marked by 0, 1, 2, 3, 4, or 5 R groups. gg Group substitution, or two geminal radicals dd Substituents can combine to form =O or =S;

[0138] R eeEach is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, and heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl is independently surrounded by 0, 1, 2, 3, 4, or 5 R groups. gg Group substitution;

[0139] R ff Each is independently selected from hydrogen, alkyl, haloalkyl, alkenyl, ynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl, or two R ff The groups combine to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl group is independently bounded by 0, 1, 2, 3, 4, or 5 R groups. gg Group substitution;

[0140] R gg Each of these is independently: halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1-6 Alkyl, -ON(C) 1-6 Alkyl)2, -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + X - -NH(C 1-6 Alkyl)2 + X - -NH2(C 1-6 alkyl) + X - -NH3 + X - -N(OC) 1-6 Alkyl)(C 1-6 Alkyl), -N(OH)(C 1-6 Alkyl groups, -NH(OH), -SH, -SC 1-6 Alkyl, -SS(C 1-6 Alkyl), -C(=O)(C 1-6 Alkyl group, -CO2H, -CO2(C 1-6 Alkyl), -OC (=O)(C 1-6 Alkyl), -OCO2(C 1-6 Alkyl groups, -C(=O)NH2, -C(=O)N(C 1-6 Alkyl)2、-OC(=O)NH(C 1-6 Alkyl), -NHC(=O)(C 1-6 alkyl), -N(C) 1-6 Alkyl)C(=O)(C 1-6 alkyl), -NHCO2(C 1-6 Alkyl), -NHC(=O)N(C1-6 Alkyl)2、-NHC(=O)NH(C 1-6 Alkyl groups, -NHC(=O)NH2, -C(=NH)O(C 1-6 Alkyl), -OC (=NH)(C 1-6 Alkyl group), -OC (=NH)OC 1-6 Alkyl group, -C(=NH)N(C 1-6 Alkyl)2、-C(=NH)NH(C 1-6 Alkyl groups, -C(=NH)NH2, -OC(=NH)N(C 1-6 Alkyl)2、-OC(NH)NH(C 1-6 Alkyl groups, -OC(NH)NH2, -NHC(NH)N(C 1-6 Alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1-6 alkyl), -SO2N(C 1-6 alkyl)2、-SO2NH(C 1-6 Alkyl groups, -SO2NH2, -SO2C 1-6 Alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C) 1-6 Alkyl)3、-OSi(C 1-6 Alkyl)3, -C(=S)N(C 1-6 Alkyl)2、C(=S)NH(C 1-6 Alkyl), C(=S)NH2, -C(=O)S(C 1-6 Alkyl), -C(=S)SC 1-6 Alkyl, -SC (=S)SC 1-6 Alkyl group, -P(=O)2(C 1-6 Alkyl), -P(=O)(C 1-6 Alkyl)2、-OP(=O)(C 1-6 Alkyl)2、-OP(=O)(OC 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Haloalkyl, C2-C6 alkenyl, C2-C6 ynyl, C3-C7 cycloalkyl, C6-C 10 Aryl, C3-C7 heterocyclic, C5-C 10 heteroaryl; or two ethryl groups gg Substituents can combine to form =O or =S; where X - It is a counterion.

[0141] Exemplary substituents on the nitrogen atom include, but are not limited to: hydrogen, -OH, -ORaa -N(R) cc )2、-CN、-C(=O)R aa -C(=O)N(R) cc )2、-CO2R aa -SO2R aa -C(=NR) bb )R aa -C(=NR) cc OR aa -C(=NR) cc )N(R cc )2、-SO2N(R cc )2、-SO2R cc -SO2OR cc -SOR aa -C(=S)N(R) cc )2、-C(=O)SR cc -C(=S)SR cc -P(=O)2R aa -P(=O)(R aa )2、-P(=O)2N(R cc )2、-P(=O)(NR cc 2. Alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl, or two R atoms attached to a nitrogen atom. cc The groups combine to form a heterocyclic or heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, and heteroaryl group is independently bounded by 0, 1, 2, 3, 4, or 5 R groups. dd Group substitution, wherein R aa R bb R cc and R dd As stated above.

[0142] "Nucleic acid" refers to single-stranded or double-stranded deoxyribonucleic acid (DNA) or nucleic acid (RNA) molecules and their hybrid molecules.

[0143] In one embodiment of the present invention, the ionizable cationic lipid refers to the lipid molecule of the present invention. In a further embodiment, it may also refer to a combination of the lipid molecule of the present invention and ionizable cationic lipids known in the prior art. The ionizable cationic lipids known in the prior art are selected from 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), 4-(dimethylamino)butyric acid (6,9,28,31-tetraen-19-yl)heptadecyl alcohol ester (DLin-MC3-DMA), 1,2-dioleoyl... -3-Dimethylammonium propane (DODAP), N-(4-carboxybenzyl)-N,N-dimethyl-2,3-bis(oleoyloxy)prop-1-ammonium (DOBAQ), YSK05, 4-(((2,3-bis(oleoyloxy)propyl)-(methyl)amino)methyl)benzoic acid (DOBAT), N-(4-carboxybenzyl)-N,N-dimethyl-2,3-bis(oleoyloxy)prop-1-ammonium (DOBAQ), 3-((2,3-bis)propane (oleoyloxy)propyl)(methyl)amino)propionic acid (DOPAT), N-(2-carboxypropyl)-N,N-dimethyl-2,3-bis-(oleoyloxy)-prop-1-ammonium (DOMPAQ), N-(carboxymethyl)-N,N-dimethyl-2,3-bis(oleoyloxy)-prop-1-ammonium (DOAAQ), Alny-100, 3-(dimethylamino)propyl(12Z,15Z)-3-[(9Z,12Z)-decanoic acid] One or more of the following: [octadeca-9,12-dien-1-yl]-tetradecano-12,15-dien ester (DMAP-BLP) and derivatives of ionizable amino lipids, SM-102, ALC-0315, MC3, 8-[(2-hydroxyethyl)(6-oxo-6-decoxyhexyl)amino]octanoic acid (heptadecano-9-yl) ester or [(4-hydroxybutyl)azadiyl]bis(hexane-6,1-diyl)bis(2-hexyldecanoate).

[0144] "Cationic lipids" refer to lipid molecules that can carry a positive charge under physiological pH conditions. In some embodiments, cationic lipids are amino lipids.

[0145] "Neutral lipids" refer to lipid molecules that are uncharged under specific pH conditions, such as physiological pH conditions. Examples of neutral lipids include, but are not limited to, 1,2-distearyl-sn-glycerol-3-phosphate choline (DSPC), 1,2-dimyristoyl-sn-glycerol-3-phosphate choline (DMPC), 1,2-dioleoyl-sn-glycerol-3-phosphate choline (DOPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline (DPPC), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate choline (POPC), 1,2-dioleoyl-sn-glycerol-3-phosphate ethanolamine (DOPE), 1,2-dimyristoyl-sn-glycerol-3-phosphate ethanolamine (DMPE), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate ethanolamine (POPE), and 1,2-dipalmitoyl-sn-glycerol-3-phosphate ethanolamine (DPPE).

[0146] "Structural lipids" refer to lipids that enhance the stability of nanoparticles by filling the gaps between lipids, such as steroids. Steroids are compounds with a cyclopentane-polyhydrophenanthrene carbon skeleton. In a preferred embodiment, the steroid is selected from cholesterol, sitosterol, coccosterol, rock saponin, campesterol, ergosterol, tomatine, ursolic acid, α-tocopherol, stigmasterol, alfalfa sterol, ergocalciferol, or campesterol.

[0147] "Polymer lipid" refers to a molecule containing both a polymer portion and a lipid portion. In some embodiments, the polymer lipid is a polyethylene glycol (PEG) lipid.

[0148] The term "fat-soluble vitamin residue" refers to residues derived from fat-soluble vitamins, as well as residues derived from derivatives obtained by appropriately converting hydroxyl, aldehyde, or carboxylic acid (which are functional groups in fat-soluble vitamins) into other reactive functional groups. Examples of fat-soluble vitamins include retinoic acid, retinol, retinaldehyde, ergosterol, 7-dehydrocholesterol, calciferol, cholecalciferol, dihydroergocalciferol, dihydrotachysterol, tocopherol, tocotrienol, etc. Preferred examples of fat-soluble vitamins include retinol, tocopherol, or tocotrienol.

[0149] The term "fatty acid" refers to a carboxylic acid having an aliphatic chain, which can be saturated or unsaturated. That is, a fatty acid is composed of a hydrocarbon group consisting of carbon and hydrogen linked to a carboxyl group, and has 4 to 30 carbon atoms, preferably 8 to 22 (including the carbon atoms of the carboxyl group), and more preferably 14 to 22. Examples of saturated fatty acids include caprylic acid (C8), capric acid (C10), lauric acid (C12), myristic acid (C14), palmitic acid (C16), stearic acid (C18), arachidic acid (C20), or docosuccinic acid; examples of unsaturated fatty acids include monounsaturated fatty acids such as myristoleic acid (C14:1, cis-9), palmitoleic acid (C16:1, cis-9), oleic acid (C18:1, cis-9), trans oleic acid (C18:1, trans-9), ricinoleic acid (C18:1, cis-9), or polyunsaturated fatty acids such as linolenic acid, DHA, and EPA.

[0150] The term "fatty alcohol" refers to an alcohol having an aliphatic chain, which can be saturated or unsaturated. That is, a fatty alcohol is composed of hydrocarbon groups linked to hydroxyl groups, and has 4-30 carbon atoms, preferably 8-22 (including the carbon atom containing the carboxyl group). Preferred examples include 3,6,8-dodecane-1-ol, 1-hexadecane-1-ol, 1-octadecane-1-ol, 7-hydroxymethyl-3,11,15-trimethyl-2,6,10,14-hexadecane-1-ol, 1,9-heptadecadien-4,6-diyne-3,8-diol, 1-triacontanol, 10,12-hexadecadien-1-ol, 1-dococaptanol, 14-methyl-1-hexadecane-1-ol, 14-methyl-1-pentadecanol, and (Z,Z)-1-(ethylhexadecane-1-ol). Acyloxy)-2-hydroxy-12,15-tetradecadien-4-one, (2R,3S,4S,5E,7S,8S,9R)-2,9-dihydroxy-3,4,7,8-diepoxy-undec-5,10-diene, 14-O-acetyl-8,9(E)-10,11(E)-diepoxy-12(E)-en-2,4,6-triyne-tetradecane-1-ol, 10-propyl-5,9-tetracene-1-ol, 13-tetradecene-2,4-diyne-1-ol, 2,2,9,9-tetramethyl-decane-1,10-diol, (3S,8E)-1,3-dihydroxy-8-decen-5-one, 1,9(Z)-heptadecadien-4,6- diyn-3-ol, 5,7-dodecen-1-ol, 11-dodecen-1-ol, 2,9-heptadecen-4,6-diyne-1,8-diol, 7,11-hexadecen-1-ol, 9-dodecen-1-ol, 10-dodecen-1-ol, (E,Z)-7,9-dodecen-1-ol, 1-heptadecen-4,6-diyne-3,9,10-triol, 9,10-epoxy-1-heptadecen-4,6-diyne-3-ol, 1,9(Z),16-heptadectrien-4,6-diyne-3,8-diol, 9-hexadecenen-1-ol, 7(R)-methyl-6(E)-nonen-3-ol, 3-methyl-6-(1-methylethyl)-3,9 -decadien-1-ol, 3,5-dodecadien-1-ol, 14-methyl-8-hexadiendecen-1-ol, 10-methyl-1-dodecylol, (3S,7S)-dimethyl-tetrazol, 10-chloro-3,9-dihydroxyheptadecyl-1-ene-4,6-diyne, (3S,7S)-dimethyl-tetradecyl-2-ol, (S)-(-)-3-(9-hydroxynonyl)-1-cyclopentene, (R)-(+)-3-(9-hydroxynonyl)-1-cyclopentene(ynyl)-1-cyclopentene, 1-tetradecylol, 5-decen-1-ol, (7E)-decen-1-ol, (3S,7S)-dimethyl-hexadecyl-2-ol, (8Z)-dodecen-1-ol, (8E,10E)-dodecen-1-ol, (Z,Z)-3,13-octadecen-1-ol, (E,Z)-3,13-octadecen-1-ol, (7E)-dodecen-1-ol, 9-pentadecadecen-1-ol, (11Z)-eicosene-1-ol, (Z)-11-heptadecen-1-ol, (E,Z)-6-11-hexadecen-1-ol, (Z,Z)-6,11-hexadecen-1-ol, (Z)-7-hexadecen-1-ol, (Z)-11-hexadecen-1-ol, (E,Z)-2,13-octadecen-1-ol.

[0151] "Lipid nanoparticles (LNPs)" refer to particles containing lipid components and having a nanoscale size. Lipid nanoparticles include the aforementioned ionizable cationic lipids, structural lipids, auxiliary lipids, and surfactants. In some embodiments, the total molar content of ionizable cationic lipids, structural lipids, auxiliary lipids, and surfactants is 100% by molar percentage (mol%).

[0152] In some embodiments, the lipid nanoparticles comprise 20-60 mol% of the above-described ionizable cationic lipids, 25-55 mol% of structural lipids, 5-25 mol% of auxiliary lipids, and 0.5-15 mol% of surfactants.

[0153] In some embodiments, the structural lipid is selected from cholesterol and cholesterol derivatives, preferably cholesterol.

[0154] In some embodiments, the assisting lipid is selected from DSPC, DOPE, DOPC, DOPG, or DOPS, preferably DSPC.

[0155] In some embodiments, the surfactant is selected from PEG2000-DMG, PEG-DSPE, DTDA-PEG2000, TPGS, and preferably PEG2000-DMG.

[0156] In some embodiments, the lipid nanoparticles comprise 20-50 mol% ionizable cationic lipids. For example, the lipid nanoparticles may comprise 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 mol% ionizable cationic lipids.

[0157] In other embodiments, the lipid nanoparticles comprise 50-60 mol% ionizable cationic lipids. For example, the lipid nanoparticles may comprise 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 mol% ionizable cationic lipids.

[0158] In some embodiments, the lipid nanoparticles contain 5-25 mol% DSPC, preferably 2-15 mol% DSPC; for example, the lipid nanoparticles may contain 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 mol% DSPC.

[0159] In some embodiments, the lipid nanoparticles contain 25-55 mol% cholesterol, preferably 30-40 mol% cholesterol. For example, the lipid nanoparticles may contain 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 mol% cholesterol.

[0160] In some embodiments, the lipid nanoparticles contain 0.5-15 mol% DMG-PEG, preferably 1-2 mol% DMG-PEG. For example, the lipid nanoparticles may contain 1, 1.5, or 2 mol% DMG-PEG.

[0161] In some embodiments, the lipid nanoparticles comprise 50 mol% ionizable cationic lipids, 10 mol% DSPC, 38.5 mol% cholesterol, and 1.5 mol% DMG-PEG.

[0162] Other definitions

[0163] The terms “optional,” “arbitrary,” “optionally,” or “arbitrarily” refer to events or conditions that are subsequently described but are not required to occur, and the description includes both cases where said events or conditions occur and cases where said events or conditions do not occur.

[0164] As used herein, the term “treatment” refers to reversing, alleviating, inhibiting, or preventing the progression of an obstacle or condition to which the term applies, or one or more symptoms of such an obstacle or condition. The noun “treatment” as used herein also refers to the action of the verb “to treat,” as defined above.

[0165] As used herein, the term "pharmaceutically acceptable salt" refers to carboxylates and amino acid addition salts of the compounds of the present invention that are suitable for contact with patient tissues within the limits of reliable medical judgment, without producing undue toxicity, irritation, allergic reactions, etc., and are effective for their intended use in proportion to a reasonable benefit / risk ratio, including (where possible) zwitterionic forms of the compounds of the present invention.

[0166] Pharmaceutically acceptable base addition salts are those formed with metals or amines, such as alkali metal and alkaline earth metal hydroxides or organic amines. Examples of metals used as cations include sodium, potassium, magnesium, and calcium. Suitable amines include N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucosamine, and procaine.

[0167] The base addition salts of acidic compounds can be prepared by contacting the free acid form with a sufficient amount of the required base in a conventional manner to form a salt. The free acid can be regenerated by contacting the salt form with an acid in a conventional manner and then separating the free acid. The free acid forms differ somewhat from their respective salt forms in certain physical properties, such as solubility in polar solvents; however, for the purposes of this invention, the salts are equivalent to their respective free acids.

[0168] Salts can be sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, and iodides prepared from inorganic acids, such as hydrochloric acid, nitric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, and phosphoric acid. Representative salts include: hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, toluenesulfonate, citrate, maleate, fumarate, succinate, tartrate, naphthate, methanesulfonate, gluconate, lactobionate, laurylsulfonate, and hydroxyethanesulfonate. Salts can also be prepared from organic acids, such as aliphatic monocarboxylic and dicarboxylic acids, phenyl-substituted alkyl acids, hydroxyalkyl acids, alkyl diacids, aromatic acids, and aliphatic and aromatic sulfonic acids. Representative salts include acetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinates, caprylates, sebacic acid salts, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, naphthates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, maleates, tartrates, and methanesulfonates. Pharmaceutically acceptable salts may include alkali metal and alkaline earth metal-based cations, such as sodium, lithium, potassium, calcium, and magnesium, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine. Salts of amino acids are also included, such as arginine salts, gluconates, and galacturonic acids (see, for example, Berge S. et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977; 66:1-19, incorporated herein by reference).

[0169] The term "subject" in the administration includes, but is not limited to: humans (i.e., men or women of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or older adults)) and / or non-human animals, such as mammals, e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human animal. The terms "human," "patient," and "subject" are used interchangeably herein.

[0170] The terms “disease,” “disorder,” and “symptom” are used interchangeably in this article.

[0171] Unless otherwise stated, the term “treatment” as used herein includes effects that occur when a subject has a specific disease, disorder, or condition, which reduce the severity of the disease, disorder, or condition, or delay or slow the development of the disease, disorder, or condition (“therapeutic treatment”), and also includes effects that occur before a subject begins to have a specific disease, disorder, or condition (“preventive treatment”).

[0172] Generally, the "effective amount" of a compound refers to the amount sufficient to elicit a target biological response. As will be understood by those skilled in the art, the effective amount of the compounds of the present invention can vary depending on factors such as the biological target, the pharmacokinetics of the compound, the disease being treated, the administration method, and the age, health status, and symptoms of the subject. Effective amounts include therapeutic effective amounts and prophylactic effective amounts.

[0173] Unless otherwise stated, the term "therapeuticly effective amount" of a compound as used herein is an amount sufficient to provide therapeutic benefit in the treatment of a disease, disorder, or condition, or to delay or minimize one or more symptoms associated with the disease, disorder, or condition. Therapeuticly effective amount of a compound refers to the amount of a therapeutic agent, used alone or in combination with other therapies, that provides therapeutic benefit in the treatment of a disease, disorder, or condition. The term "therapeuticly effective amount" may include amounts that improve overall treatment, reduce or prevent symptoms or causes of a disease or condition, or enhance the therapeutic effects of other therapeutic agents.

[0174] Unless otherwise stated, the “preventively effective amount” of a compound as used herein is an amount sufficient to prevent a disease, disorder, or condition, or an amount sufficient to prevent one or more symptoms associated with a disease, disorder, or condition, or an amount sufficient to prevent recurrence of a disease, disorder, or condition. The preventively effective amount of a compound refers to the amount of a therapeutic agent, used alone or in combination with other agents, that provides preventive benefit in the prevention of a disease, disorder, or condition. The term “preventively effective amount” may include amounts that improve overall prevention or enhance the preventive effect of other preventive agents.

[0175] The term "combination" and related terms refer to the simultaneous or sequential administration of the compounds of the present invention and other therapeutic agents. For example, the compounds of the present invention may be administered simultaneously or sequentially with other therapeutic agents in separate unit dosage forms, or simultaneously with other therapeutic agents in a single unit dosage form.

[0176] I. Preparation Examples

[0177] 1. Synthesis Example 1

[0178] 1.1A Synthesis

[0179] Add 85 g of compound A1 and 29.8 g of compound a(CH3(CH2)) to 800 ml of DCM. 11 OH), 1.96 g DMAP and 33.7 g EDCI were added and reacted at 20 °C for 12 hours. TLC (PE / EA = 3 / 1) showed that the reaction of A1 was complete. The reaction solution was poured into 1000 ml of water, extracted with DCM, and purified by column chromatography to obtain 77 g of white solid compound A2.

[0180] 70 g of compound A2 was added to 700 ml of THF. 9.68 g of NaH (60%) was added in portions at 0 °C and stirred for 30 minutes. Then, 57.2 g of CH3I was added dropwise. After the addition was complete, the mixture was stirred at 20 °C for 12 hours. The reaction was detected by TLC (PE / EA = 5 / 1). The reaction was quenched at 0 °C with 1000 ml of NH4Cl. The mixture was extracted with 2000 ml (1000 ml * 2) of EA. The mixture was separated, and the organic phase was washed with 1000 ml of saturated brine. The organic phase was dried and purified by column chromatography to obtain 57 g of colorless oil (compound A3).

[0181] Add 57 g of compound A3 and 13.5 g of Pd / C (10%) to 500 ml of THF, under nitrogen protection, and then replace with H2 three times. React at 40 °C for 3 hours under H2 (1.5 MPa). Monitor the reaction for completeness by TLC (PE / EA = 3 / 1). Filter and concentrate to obtain 34 g of colorless oil (compound A4).

[0182] At 0°C, 73.4 g of TrtSH (triphenylmethylthiol) and 26.8 g of TEA were added to 1600 ml of THF and stirred for 30 minutes. Then, 40 g of compound A7 was added dropwise and reacted at 20°C for 2 hours. The reaction was completed by TLC (PE / EA = 5 / 1). The reaction solution was poured into 2000 ml of water and extracted with EA (2000 ml * 2). The organic phase was washed with 2000 ml of saturated brine, dried over Na2SO4, evaporated to dryness, and purified by column chromatography to obtain 50 g of white solid (compound A5).

[0183] 10g of compound A5, 8.83g of compound A4, 3.22g of NaBH3CN (sodium cyanoborohydride), 2.31g of acetic acid, and 10.9g of Ti(i-PrO)4 (tetraisopropoxytitanium) were added to 100ml of ethanol. The mixture was reacted at 80℃ for 12 hours. Since the starting material was not completely reacted, 1000ml of methanol was added to the reaction mixture. The mixture was filtered, the filtrate was evaporated to dryness, and purified by column chromatography to obtain 3.5g of a yellow oily substance (compound A6).

[0184] Characterization data of compound A6: Molecular formula: C 41 H 59 NO3S; Molecular weight: 645.42, LCMS: m / z = 646.5 [M+1] + ; 1 H NMR: (400MHz, DMSO-d6) δ9.06-8.69(m,1H),7.46-7.25(m,15H),5.78-5.36(m,1H),4.11-3.90(m,2H), 3.71-3.51(m,3H),3.02-2.61(m,5H),2.46-2.36(m,1H),2.34-2.25(m,2H),1.62-1.47(m,4H),1.40(br s, 2H), 1.35-1.10 (m, 20H), 0.85 (t, J = 6.8Hz, 3H).

[0185] Add 500 mg of compound A6 and 99 mg of triethylsilane to 5 ml of DCM, cool to 0 °C and add 5 ml of TFA dropwise. After the addition is complete, react at room temperature for 1.5 h. The reaction is completed by TLC and then evaporated to dryness for later use.

[0186] 1.2 Synthesis of Compound B

[0187] Step 1 process:

[0188] 150 g of mercapto-based raw material (Trt-SH) was added to 3 L of THF. 217 mL of 2.5 M n-butyllithium was added dropwise under a nitrogen atmosphere below 0 °C. The mixture was stirred at 0 °C for 0.5 h. Then, the temperature was lowered to -78 °C and 479 g of dibromoethane was added dropwise. The mixture was stirred for 0.5 h. The temperature was slowly raised to room temperature and stirred for 0.5 h. TLC showed that the reaction was complete. The reaction was quenched with 500 mL of saturated ammonium chloride aqueous solution. The mixture was extracted with EA (3 × 1000 mL) and evaporated to dryness to obtain 160 g of product.

[0189] Second step of the process:

[0190] 60 g of the product from the first step and 40.4 g of piperidinol were added to 600 ml of dioxane, followed by 65 g of K2CO3 and 13 g of KI. The mixture was then reacted at 110 °C for 12 h under nitrogen protection. The reaction was monitored by TLC until complete. The mixture was filtered, the filtrate was evaporated to dryness, and purified by column chromatography to obtain 56.4 g of white solid.

[0191] Third step of the process

[0192] Add 50 g of vitamin E to 250 ml of SOCl2 and react at 50 °C for 2 h. Directly evaporate to dryness and dissolve in 300 ml of DCM for later use. Dissolve 40.7 g of the product from the second step and 28.6 g of triethylamine in 200 ml of DCM and cool to 0 °C. Add acyl chloride dropwise at 0 °C. After the addition is complete, react at 25 °C for 12 h. Monitor the reaction for completeness by TLC. After evaporating to dryness, pour into 200 ml of water and adjust the pH to 8 with NaHCO3. Extract with DCM (2 × 200 ml). Separate the liquid and evaporate the organic phase to dryness. Purify by column chromatography to obtain 53 g of oil.

[0193] Fourth step process

[0194] Add 30 g of the product from the previous step, 21 g of dithiopyridine, and 4 g of triethylsilane to 300 ml of DCM. Cool to 0 °C and add 300 ml of TFA dropwise. After the addition is complete, react at room temperature for 3 h. Monitor the reaction by TLC until it is complete. Rotate the reaction solution to dryness and purify by column chromatography to obtain 20 g of product B.

[0195] Characterization data of compound B: Molecular formula: C 47 H 74 N₂O₅S₂; Molecular weight: 810.50, LCMS: m / z = 811.5 [M+1] + ; 1 H NMR: DMSO-d6, 400MHz, δ8.50 (d, J=4.4Hz, 1H), 7.92-7.81 (m, 1H), 7.74 (d, J=8.0 Hz,1H),7.35-7.25(m,1H),4.08(t,J=6.4Hz,2H),3.56-3.45(m,2H),3.23-3.15( m,2H),2.95-2.79(m,4H),2.72-2.63(m,2H),2.60-2.52(m,2H),2.04-1.98(m,3H ),1.95-1.81(m,8H),1.77-1.71(m,2H),1.67-0.91(m,31H),0.88-0.76(m,12H).

[0196] 1.3 Synthesis of Compound C

[0197] Synthesis of compound C2

[0198] In a 500ml three-necked flask, add DCM (240ml), compound C1 (24g), compound 1a (47g), EDCI (18.7g), and DMAP (1.08g), and stir at room temperature for 12 hours. TLC (PE:EA = 10:1) showed a small amount of C1 remaining. The reaction mixture was transferred to water (500ml), extracted with DCM (200ml x 2), and the extract was separated, evaporated to dryness, and column chromatography to obtain 25g of product.

[0199] Synthesis of compound C3

[0200] In a 500ml three-necked flask, add 250ml of THF, 25g of compound C2, and 2.9g of NaH (60% purity). Cool to 0°C and add 17.1g of iodomethane dropwise at 0°C. After the addition is complete, stir at room temperature for 12 hours. Monitor the remaining small amount of C2 by TLC (PE:EA = 10:1). Quench the reaction with 100ml of NH4Cl. Extract with EA (100ml*2). Wash the organic phase with 100ml of saturated brine, dry to anhydrous sodium sulfate, filter, evaporate to dryness, and purify by column chromatography to obtain 18g of product.

[0201] Synthesis of compound C4

[0202] Methanol (180 ml), compound C3 (18 g), and 5% palladium on carbon (2 g) were added to a hydrogenation flask. The mixture was purged with nitrogen, followed by three purgings with hydrogen. The reaction was then carried out at 1.00 MPa for 12 h. TLC (PE:EA = 10:1) showed that the reaction was complete. The mixture was filtered, and the reaction solution was evaporated to dryness to give 12 g of product.

[0203] Synthesis of compound C

[0204] Compound C4 (2.8 g), ethanol (28 ml), compound C5 (2.5 g), NaBH3CN (2.73 g), acetic acid (576 mg), and Ti(i-PrO)4 (2.73 g) were added to a three-necked flask (100 ml). The reaction was then carried out at 80 °C for 12 h. LC-MS showed that 660 mg of product was obtained by column chromatography.

[0205] Characterization data of compound C: Molecular formula: C 47 H 71 NO3S; Molecular weight: 730.15, LCMS: m / z = 731.4, [M+1] + ; 1H NMR: DMSO-d6, 400MHz, δ7.32(d,J=4.0Hz,12H),7.27-7.20(m,3H),4.85-4.72(m,1H),4.32-4.14(m,1H),3.21-3.12(m ,1H),2.32-2.18(m,5H),2.16-2.08(m,1H),2.03(s,3H),1.56-1.42(m,6H),1.36-1.12(m,32H),0.84(t,J=6.8Hz,6H).

[0206] 1.4 Synthesis of Compound D

[0207] Synthesis of compound D2

[0208] Add succinic anhydride (4.0 g), DCM (50 ml), and DMAP (6.1 g) to a 100 ml three-necked flask. Add the starting compound D1 (4.8 g) while stirring, and stir at room temperature for 6 h. Adjust the pH to 1-2 with 1 N hydrochloric acid, separate the contents, wash with saturated brine, dry, concentrate, and purify by column chromatography to obtain 3.2 g of product.

[0209] Synthesis of compound D3

[0210] Under nitrogen protection, add 50 ml of dichloroethane and 2.6 g of the starting compound D2 to a 100 ml three-necked flask, stir and cool to 0 °C, add 1.65 g of thionyl chloride, heat to 50 °C, stir for 2 h, concentrate the reaction solution to dryness, and then add 10 ml of (DCM) for later use.

[0211] Under nitrogen protection, 50 ml of (DCM) and 3.0 g of starting compound D4 were added to a 100 ml three-necked flask. Triethylamine (2.2 g) was added with stirring, followed by the addition of the prepared solution. After the addition was complete, the mixture was reacted at 35 °C for 8 h. The reaction solution was washed with water, dried, concentrated, and purified by column chromatography to obtain 2.6 g of product.

[0212] Synthesis of compound D

[0213] Add DCM (50 ml), starting compound D3 (2.2 g), dithiopyridine (1.9 g), and triethylsilane (0.36 g) to a 100 ml three-necked flask. Cool to 0 °C and add TFA (40 ml) dropwise. After the addition is complete, react at room temperature for 3 h. Monitor the reaction by TLC until it is complete. The reaction solution is evaporated to dryness and purified by column chromatography to obtain compound D (0.5 g).

[0214] Characterization data of compound D: Molecular formula: C 36 H 60 N₂O₄S₂; Molecular weight: 649, LCMS: m / z = 649.2, [M]+ ; 1 H NMR: DMSO-d6, 400MHz: δ8.50(d,J=4.4Hz,1H),7.92-7.81(m,1H),7.74(d,J=8.0Hz,1H),7.35-7.25(m,1H),5.28(t,J=6.4Hz,2H),4.21 -4.10(m,4H),3.58-3.40(m,6H),3.51-3.10(m,6H),2.80-2.75(m,2H),2.66-2.48(m,12H),2.32-2.25(m,2H),2.04-1.92(m,6H),1.30 -1.25(m,13H),0.87-0.83(m,3H).

[0215] 1.5 Synthesis of target compound T(A+B)

[0216] Compound A was dissolved in 5 ml of DCM, and 659 mg of compound B was added. The mixture was stirred overnight at room temperature, evaporated to dryness, and purified by column chromatography to obtain 300 mg of the product.

[0217] Characterization data of compound T(A+B): Molecular formula: C 64 H 114 N2O8S2; Molecular weight: 1103.74, LCMS: m / z = 1103.8, [M]; 1 H NMR: (400MHz, CDCl3): δppm: 4.30-4.18(m,2H),4.17-4.11(m,4H),4.10-4.05(m,1H),4.11-3.90 (m,2H),3.60-3.50(m,2H),3.25-3.20(m,2H),3.15-3.05(m,2H),3.00-2.82(m,4H),2.80-2.72(m ,2H),2.70-2.60(m,4H),2.35-2.28(m,1H),2.35-2.28(m,1H),2.10(s,3H),2.07(s,3H),2.03(s, 3H),1.99(s,3H),1.90-1.75(m,6H),1.74-1.49(m,12H),1.48-1.00(m,41H),0.95-0.08(m,15H).

[0218] 1.6 Synthesis of the target compound (A+D)

[0219] In a single-necked flask, compound A6 (250 mg) was dissolved in DCM (5 ml), and trimethylsilane (135 mg) was added. Trifluoroacetic acid (1.37 g) was added dropwise in an ice bath. The mixture was stirred at room temperature for 2 h. The reaction was completed by TLC (PE:EA = 1:1). The mixture was then evaporated to dryness, and DCM (5 ml) was added to dissolve the compound A6. Compound D (264 mg) was added, and the mixture was stirred at room temperature for 48 h. TLC (PE:EA:MeOH = 5:4:1) showed that a small amount of starting compound D remained. The mixture was evaporated to dryness and purified by column chromatography to obtain 50 mg of the product.

[0220] Characterization data of compound (A+D): Molecular formula: C 53 H 100 N2O7S2; Molecular weight: 941.51, LCMS: m / z = 959.96, [M+NH4] + ]; 1 H NMR: (400MHz, CDCl3): δppm: 5.56-5.53(m,1H),5.31-5.29(m,1H),5.00-4.25(m,6H),4.20-4.10(m,1H),4.09-4.01(m,2H),3.98-3.85(m,1H),3. 68-3.49(m,1H),3.28-3.23(m,2H),2.82-1.70(m,6H),2.37-2.26(m,8H) ,2.09(d,8H),1.69-1.42(m,20H),1.40-1.12(m,36H),0.90-0.85(m,6H).

[0221] 1.7 Synthesis of the target compound (C+B)

[0222] In a single-necked flask, compound C (250 mg) was dissolved in DCM (5 ml), and trimethylsilane (119 mg) was added. Trifluoroacetic acid (1.21 g) was added dropwise in an ice bath. The mixture was stirred at room temperature for 2 h. The reaction was completed by TLC (PE:EA = 1:1). The mixture was then evaporated to dryness, and DCM (5 ml) was added to dissolve the compound C. Compound B (291.7 mg) was added, and the mixture was stirred at room temperature for 48 h. TLC (PE:EA:MeOH = 5:4:1) showed that a small amount of starting compound B remained. The mixture was then evaporated to dryness and purified by column chromatography to obtain 48 mg of the product.

[0223] Characterization data of compound (C+B): Molecular formula: C 70 H 126 N2O8S2; Molecular weight: 1187.90, LCMS: m / z = 1187.91, [M]; 1H NMR: (400MHz, CDCl3): δppm: 4.92-4.82(m,1H),4.35-4.28(m,1H),4.22-4.12( m,3H),3.82-3.71(m,1H),3.50-3.40(m,2H),3.26-2.81(m,12H),2.80-2.70(m, 3H),2.68-2.44(m,6H),2.41-2.15(m,8H),2.13-2.05(s,3H),2.04-1.99(s,3H) ,1.98-1.93(s,3H),1.89-1.02(m,59H),1.00-0.92(m,2H),0.91-0.08(m,18H).

[0224] 1.8 Synthesis of the target compound (C+D)

[0225] In a single-necked flask, compound C (250 mg) was dissolved in DCM (5 ml), and trimethylsilane (119 mg) was added. Trifluoroacetic acid (1.21 g) was added dropwise in an ice bath. The mixture was stirred at room temperature for 2 h. The reaction was completed by TLC (PE:EA = 1:1). The mixture was then evaporated to dryness, and DCM (5 ml) was added to dissolve the compound C. Compound D (233 mg) was then added. The mixture was stirred at room temperature for 48 h. TLC (PE:EA:MeOH = 5:4:1) showed that a small amount of starting compound D remained. The mixture was evaporated to dryness and purified by column chromatography to obtain 92 mg of the product.

[0226] Characterization data of compound (C+D): Molecular formula: C 59 H 112 N2O7S2; Molecular weight: 1025.67, LCMS: m / z = 1025.76, [M]; 1 H NMR: (400MHz, CDCl3): δppm: 5.56-5.53(m,1H), δ5.31-5.29(m,1H), δ4.90-4. 78(m,2H),δ4.34-4.27(m,1H),δ4.26-4.05(m,4H),δ3.93-2.82(m,7H),δ2.35- 2.25(m,6H),δ2.06-2.02(m,3H),δ1.92-1.80(m,4H),δ1.78-1.60(m,8H),δ1.5 8-1.37(m,16H), δ1.36-1.16(m,45H), δ0.99-0.91(m,4H), δ0.91-0.83(m,9H).

[0227] Following the synthetic method described above, the following compounds were synthesized:

[0228] in:

[0229] n-12 alkyl:

[0230] n-18-alkyl-9-yl:

[0231] VE:

[0232] VA (Retinol):

[0233] VD (VD2, VD3 or mixtures thereof):

[0234] Cholesterol base:

[0235] trans-9-octadecenyl:

[0236] II. Pharmacological Experiments

[0237] Experimental Example 1: Preparation of Nanoparticles

[0238] Materials used for assembling lipid nanoparticles include: (1) ionizable lipid compounds: such as the ionizable lipid compounds designed and synthesized in this invention or SM-102 as a control group; (2) structural liposomes: such as cholesterol Cholesterol (purchased from SINOPEG); (3) phospholipids: such as DSPC (1,2-distearyl-SN-glycerol-3-phosphocholine) or DOPC (1,2-dioleoyl-sn-glycerol-3-phosphocholine); (4) polyethylene glycol-modified lipid compounds: such as DMG-PEG2000, which is dimyristic glycerol-polyethylene glycol 2000; (5) effective components of nucleic acid fragments: such as Luciferase mRNA.

[0239] Preparation method of lipid nanoparticles: (1) Ionizable lipid compounds, cholesterol, phospholipids and polyethylene glycol-modified lipids are dissolved and mixed in ethanol in proportion; (2) mRNA active ingredient is dissolved in 20mM sodium acetate solution (pH=4.0); (3) The organic phase containing the lipid mixture and the aqueous phase containing the mRNA are mixed at a flow rate of 1:1 to 1:4 using an automated high-throughput microfluidic system, with a mixing speed of 10mL / min to 18mL / min; (4) The prepared lipid nanoparticles are diluted with phosphate buffer solution and ultrafiltered to the original preparation volume using an ultrafiltration tube with a molecular weight cutoff of 100kDa; (5) The obtained nanoparticles are sterilized by filtration through a 0.2μm sterile filter membrane and then stored at low temperature in a sealed glass bottle.

[0240] Lipid nanoparticles can be prepared using microfluidic mixing systems, but are not limited to this method; other methods include T-type mixers and ethanol injection.

[0241] Experimental Example 2: Characterization of the physical properties of lipid nanoparticles

[0242] The particle size, particle size distribution index (PDI), and zeta potential of the prepared lipid nanoparticles were measured using a nanoparticle size and potential analyzer. The encapsulation efficiency (EE%) of the lipid nanoparticles was characterized, reflecting the degree of binding between the lipid nanoparticles and the RNA fragments. The concentrations of free RNA and total RNA after lysis were measured using the Ribogreen dye method.

[0243] Experiment Example 3: In vivo delivery efficiency and in situ targeting test

[0244] The delivery efficiency and safety of nanoparticles loaded with luciferase mRNA were evaluated in mice. The experimental mice were SPF-grade C57BL / 6 females, 6-8 weeks old, weighing 18-22g. All animals were acclimatized for at least 7 days before the experiment, with free access to food and water, 12h / 12h light / dark cycles, an indoor temperature of 20-26℃, and a humidity of 40-70%. Mice were randomly assigned to groups. Lipid nanoparticles loaded with luciferase mRNA were prepared according to Experiment 1 and administered intramuscularly to mice at a single dose of 0.25 mg / kg mRNA. Six hours after administration, fluorescence imaging was performed using a small animal in vivo imaging system, and data were collected and analyzed from areas of concentrated fluorescence distribution.

[0245] The particle size distribution of the LNPs formed by the control compound SM-102 and the test compounds T1-T21 is shown in Figure 8; the uniformity distribution is shown in Figure 9; the surface potential distribution is shown in Figure 10; the encapsulation efficiency is shown in Figure 11; the in vivo delivery efficiency is shown in Figure 12; and the in situ expression ratio (muscle targeting) is shown in Figure 13. These results demonstrate that the lipid nanoparticles based on the lipid compounds of this invention exhibit good uniformity, high encapsulation efficiency, and excellent delivery efficiency and muscle targeting performance.

[0246] Experiment Example 4: Safety Experiment

[0247] The experimental mice were SPF-grade BALB / c females, 6-8 weeks old, weighing 18-22g. All animals underwent acclimatization for at least 7 days prior to the experiment, with free access to food and water, 12h / 12h light / dark cycles, an indoor temperature of 20-26℃, and humidity of 40-70%. Mice were randomly assigned to groups. Blood was collected from the orbital sinus 7 days before the experiment. Lipid nanoparticles encapsulating mRNA encoding the novel coronavirus RBD protein were prepared according to Experiment Example 1 and administered intramuscularly as a single dose of 1μg mRNA. Blood was collected from the orbital sinus 8 hours after administration, and a second injection was performed 14 days later, with blood collected again 8 hours later. The liver was then dissected and harvested. After standing overnight at 4℃, serum was separated by centrifugation. The alanine aminotransferase (ALT) level in the serum was measured according to the kit instructions, and the change in level after administration compared to before administration was analyzed. The liver was ground using a high-efficiency tissue cell sample processing system, and RNA was extracted according to the kit instructions. cDNA was obtained through reverse transcription, and the levels of pro-inflammatory factors were detected by qPCR dye assay.

[0248] The results showed that neither the LNP formulation of the compounds of the present invention (WNP in the figure represents LNP prepared based on compound T5) nor the SM-102 system significantly increased the alanine aminotransferase (ALT) level in mice (Figure 14). However, compared with SM-102, mice using the LNP formulation of the compounds of the present invention produced significantly lower levels of the pro-inflammatory factor Tnfa (Figure 15). This indicates that the LNP formulation of the compounds of the present invention can effectively avoid overactivation of the immune system during RNA delivery, and has higher safety potential, which is particularly important for vaccine or treatment scenarios requiring repeated administration.

[0249] Experiment Example 5: COVID-19 Vaccine Delivery Effectiveness

[0250] The experimental mice were SPF-grade BALB / c female mice, 6-8 weeks old, weighing 18-22g. All animals underwent acclimatization for at least 7 days prior to the experiment, with free access to food and water, 12h / 12h alternating light and dark lighting, an indoor temperature of 20-26℃, and humidity of 40-70%. Mice were randomly assigned to groups. Blood was collected from the orbital sinus 7 days before the formal experiment. Lipid nanoparticles encapsulating mRNA encoding the novel coronavirus RBD protein were prepared according to Experiment Example 1. These nanoparticles were injected intramuscularly at a single dose of 1μg mRNA into mice on Day 0 and Day 14. Blood was collected from the orbital sinus on Day 14 and Day 28. Some mice were intranasally infected with the Omicron strain on Day 35. Lungs were dissected on Day 39, and livers were dissected on Day 42 in some mice (Figure 16).

[0251] The results of detecting RBD-specific binding antibodies in serum by enzyme-linked immunosorbent assay (ELISA) showed that the LNP formulation of compound T5 of the present invention could induce mice to produce high levels of RBD-specific binding antibodies comparable to those of the SM-102 system (Figure 17).

[0252] The spleen was gently ground with the syringe plunger, and the red blood cells were lysed and seeded into a 12-well plate. RBD protein was added for stimulation, and the cells were collected and the cytokine secretion level was detected by flow cytometry. It can be seen that the LNP preparation (WNP) of the compound of the present invention can induce a stronger level of cellular immunity in mice than the SM-102 system (Figure 18).

[0253] Partial lung tissue was embedded in paraffin blocks, sectioned, and stained with H&E for histopathological evaluation. A portion of the lung tissue was ground using a high-efficiency tissue and cell sample processing system, and RNA was extracted using Trizol LS. cDNA was obtained through reverse transcription, and viral titer was detected using qPCR probe method. Analysis showed that the LNP formulation of the compound of this invention produced a protective effect in mice comparable to the SM-102 system, effectively reducing the severity of lung lesions (Figure 19) and lowering the viral titer in the lungs (Figure 20).

[0254] Experimental Example 6: Rabies Vaccine

[0255] The experimental mice were SPF-grade BALB / c mice, female, 6-8 weeks old, weighing 18-22g. All animals underwent acclimatization for at least 7 days prior to the experiment, with free access to food and water, 12h / 12h alternating light and dark lighting, an indoor temperature of 20-26℃, and humidity of 40-70%. Mice were randomly assigned to groups. Blood was collected from the orbital rim of the mice 7 days before the experiment. Lipid nanoparticles encapsulating mRNA encoding the full-length G protein of rabies virus were prepared according to Experiment Example 1. These nanoparticles were administered intramuscularly to mice at single doses of 1μg mRNA and 5μg mRNA, and at a dose of 5μg subunit vaccine, on Day 0 and Day 14. Blood was collected from the orbital rim of the mice on Day 14 and Day 28.

[0256] The results of detecting G protein-specific binding antibodies in serum by enzyme-linked immunosorbent assay (ELISA) showed that the LNP preparation of compound T5 at the same dose (5 μg) could induce G protein-specific binding antibody levels in mice higher than those of the subunit vaccine. In addition, the antibody levels produced in the low-dose group (1 μg) after the initial immunization were slightly lower than those in the high-dose group (5 μg), but there was no significant difference in antibody levels after the booster immunization (Figure 21).

[0257] The level of neutralizing antibodies in serum was detected by the virus neutralization test (VNT). The results showed that after two immunizations, the LNP preparation of compound T5 at the same dose (5 μg) could produce neutralizing antibody levels in mice that were superior to those of the subunit vaccine. There was no significant difference between the low-dose (1 μg) group and the high-dose group (5 μg) (Figure 22).

Claims

1. The ionizable lipid molecule shown in Formula I: LP1 and LP2 are lipid fractions, which are independently selected from C 6-30 Alkyl, C 6-30 alkenyl or C 6-30 The alkynyl group, optionally substituted by 1, 2, 3, 4 or 5 substituents selected from: -OH, halogen, cyano, C 1-30 Alkyl, C 1-30 Halogenated alkyl groups, -OC 1-30 Alkyl, -SC 1-30 Alkyl, amino, -NH-C 1-30 Alkyl and -N(C) 1-30 Alkyl)2; or, the lipid portion is selected from or derived from steroids (such as cholesterol, sitosterol, codostrol, lycopene, campesterol, ergosterol, tomatine, ursolic acid, α-tocopherol, stigmasterol, alfalfa sterol, ergocalciferol or campesterol), fat-soluble vitamins (such as vitamin D, vitamin E, vitamin K, vitamin A) or folic acid; Where L1 and L2 are connecting portions, and the connecting portions are independently selected from bonds, -O-, -S-, -P-, -O-(HO-P=O)-O-, -N(R0)-, -CO-, -C(O)O-, -OC(O-), -C(O)NH-, -NHC(O-), -NHC(O-)NH-, and C optionally replaced by one or more R0s. 1-10 Alkylene, C 1-10 imidene group, C 1-10 The linking group is selected independently from the following: alkynyl group, 3-10 membered heterocyclic group optionally substituted with one or more R0 groups, or any combination thereof; preferably, the linking portion is selected independently from the following: α-, -O-, -S-, -P-, -O-(HO-P=O)-O-, -N(R0)-, -CO-, C- optionally substituted with one or more R0 groups. 1-10 Alkylene, 3-10 membered heterocyclic groups optionally substituted with one or more R0s, or any combination thereof; each R0 may be the same or different, and is independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, C 1-10 Alkyl, C 1-10 Alkoxy, halogenated C 1-10 Alkyl, Halogenated C 1-10 Alkyl groups; preferably, each R0 may be the same or different, and is independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkyl groups; more preferably, they are the same or different, and are independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, amino, C 1-4 Alkyl, C 1-4 Alkoxy, halogenated C 1-4 Alkyl, Halogenated C 1-4 Alkoxy; preferably, L2 contains at least one nitrogen-containing heterocyclic alkyl group; The connecting portions are optionally connected or interrupted by functional groups selected from -O-, -C(O)O-, -SC(O)O-, and -OC(O)NR. a -、-NR a C(O)NR a -、-OC(O)S-、-OC(O)O-、-NR a C(O)O-, -C(O)S-, -C(O)NR a -、-NR a C(O)S-、-SC(O)NR a -、-C(S)O-、-OC(S)NR a -、-NR a C(S)O- or click chemical groups, the R a Selected from H or methyl; Preferably, the connecting portion is C. 1-10 Straight-chain or branched alkylene groups, piperazine subunits, piperidinium subunits, -(CH2) 1-10 CO-, -O(CH2) 1-10 -、-(CH2) 1-10 C(O)O-、-(CH2) 1-10 CONH-、-O(CH2) 1-10 CO-, -O(CH2) 1-10 C(O)O-、-O(CH2) 1-10 CONH-、-OCO(CH2) 1-10 C(O)O-、-NHCO(CH2) 1-10 C(O)O-、-(CH2) 1-10 OC(O)(CH2) 1-10 CO- or a combination of the above groups; Preferably, the connecting portion is selected from -(C(G)2)a-, where a is an integer selected from 1 to 16, wherein one or more -C(G)2- can be independently and optionally replaced with -O-, -S-, -C(O)-, -C(S)-, -S(O)-, -S(O)2-, -SS-, -N(G)C(O)-, -C(O)N(G)-, -N(G)-, Or 3-10 membered heterocyclic groups; in, Each time G appears, it is independently selected from hydrogen, deuterium, halogen, hydroxyl, amino, and C. 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, or C substituted with one or more of deuterium, halogen, hydroxyl, or amino groups. 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 cycloalkyl; Where n4 is selected from integers between 0 and 4; Where n5 is selected from integers between 0 and 4; Where n6 is an integer from 1 to 5.

2. The lipid molecule as described in claim 1, wherein the compound of formula I is formula I-1: in: L 2’ L3 is the connection portion defined in claim 1; Preferably, L 2’ C 1-6 Alkyl group, L3 is C 1-12 Alkyl group, -(CH2) 1-6 O(CH2) 1-6 C(O)O-、-(CH2) 1-6 OC(O)(CH2) 1-6 C(O)O-、-(CH2) 1-6 OC(O)(CH2) 1-6 C(O)- or -(CH2) 1-6 OC(O)(CH2) 1-6 O-; G1 and G2 are either N or CH, and at least one of them is N; preferably, G1 is N and G2 is CH. G3-G6 can be either N or CH; m1 and m2 are integers from 0 to 2; preferably, one of m1 and m2 is 0 and the other is 1, or both m1 and m2 are 1, or one of m1 and m2 is 1 and the other is 2; Preferably, LP1 or LP2 is independently selected from fatty acid groups or alcohol (ether) groups derived therefrom; preferably, saturated fatty acids include caprylic acid (C8), capric acid (C10), lauric acid (C12), myristic acid (C14), palmitic acid (C16), stearic acid (C18), arachidic acid (C20), or docosuccinic acid; preferably, unsaturated fatty acids include monounsaturated fatty acids such as myristoleic acid (C14:1, cis-9), palmitoleic acid (C16:1, cis-9), oleic acid (C18:1, cis-9), trans oleic acid (C18:1, trans-9), ricinoleic acid (C18:1, cis-9), etc., or polyunsaturated fatty acids such as linolenic acid, DHA, and EPA, etc.; the alcohol (ether) groups derived therefrom refer to alcohol (or ether) groups with the same number of carbon atoms obtained by reducing the carboxyl group of the fatty acid, for example, lauric acid (C12) reduces to lauryl alcohol; n4 is an integer selected from 0 to 4; n5 is selected from integers between 0 and 4; n6 is an integer between 1 and 5.

3. The lipid molecule as described in claim 1 or 2, wherein the compound of formula I is a compound shown in formulas I-8: in, L3, LP1, LP2, n4, n5, and n6 have the definitions described in claim 1 or 2; G2 is CH or N; Preferably, the compound of formula I is the compound shown in formula I-7: Wherein, LP1, LP2, n4, n5, and n6 have the definitions described in claim 1 or 2; Preferably, LP1 is selected from C 12-22 Straight-chain aliphatic hydrocarbon groups or C 12-22 Branched aliphatic hydrocarbon groups; Preferably, LP2 is selected from or derived from fat-soluble vitamin residues, C 12-22 Straight-chain aliphatic hydrocarbon groups or C 12-22 Branched aliphatic hydrocarbon groups.

4. The lipid molecule as described in claim 1 or 2, wherein the compound of formula I is formula I-2: in, G7, G8, or G9 are H or methyl, and G2 is N or CH. It can be a single or double bond; L3 is -OC(O)(CH2). 1-9 C(O)-、-C(O)(CH2) 1-9 C(O)-、-(CH2) 1-9 C(O)-、-(CH2) 1-9 OC(O)- or -(CH2) 1-6 OC(O)(CH2) 1-6 C(O)-; Preferably, the compound of formula I is formula I-3: A further preferred option is Equation I-4: A further preferred option is formula I-4': Where G3, G4, or G5 is H or methyl. It can be a single bond or a double bond; R' and R" may be the same or different, and are independently selected from C. 2-12 Straight-chain aliphatic hydrocarbon groups or C 2-12 Branched aliphatic hydrocarbon groups.

5. The lipid molecule according to claim 1 or 2, wherein the lipid molecule is:

6. A lipid nanoparticle for local injection, comprising the ionizable lipid compound according to any one of claims 1-5; Preferably, the lipid nanoparticles further comprise neutral lipids, structural lipids, and polymeric lipids; Preferably, the lipid nanoparticles comprise ionizable lipids, neutral lipids, structural lipids, and surfactants.

7. A lipid nanoparticle composition comprising the lipid nanoparticles of claim 6 and a loading.

8. A method for preparing the lipid nanoparticle composition according to claim 7, comprising: The various lipid components are mixed and then mixed with the load.

9. A pharmaceutical composition comprising the lipid nanoparticle composition of claim 7, and pharmaceutically acceptable excipients.

10. Use of the lipid nanoparticles of claim 6, the lipid nanoparticle composition of claim 7, or the pharmaceutical composition of claim 9 in the preparation of a medicament for treating, diagnosing, or preventing a disease.

11. Use of the lipid nanoparticles of claim 6, the lipid nanoparticle composition of claim 7, or the pharmaceutical composition of claim 9 in the preparation of a medicament for delivery of a loading, wherein the loading is selected from one or more therapeutic agents, preventive agents, or diagnostic agents.

12. A method of treating, diagnosing, or preventing a disease in a subject, comprising administering to the subject the lipid nanoparticle composition of claim 7 or the pharmaceutical composition of claim 9.

13. The lipid nanoparticle composition of claim 7 or the pharmaceutical composition of claim 9, for the treatment, diagnosis or prevention of disease.

14. A method of delivering a payload into a subject, comprising administering to the subject the lipid nanoparticle composition of claim 7 or the pharmaceutical composition of claim 9.

15. The lipid nanoparticles of claim 6, the lipid nanoparticle composition of claim 7, or the pharmaceutical composition of claim 9, for delivering a payload; Preferably, the load is selected from one or more of a therapeutic agent, a preventive agent, or a diagnostic agent; preferably, the therapeutic agent, preventive agent, or diagnostic agent is a nucleic acid; More preferably, the nucleic acid is selected from one or more of ASO, RNA, or DNA; More preferably, the RNA is selected from one or more of the following: interfering RNA (RNAi), small interfering RNA (siRNA), short hairpin RNA (shRNA), antisense RNA (aRNA), messenger RNA (mRNA), modified messenger RNA (mmRNA), long non-coding RNA (lncRNA), microRNA (miRNA), small activating RNA (saRNA), multi-coding nucleic acid (MCNA), polymeric coding nucleic acid (PCNA), guide RNA (gRNA), CRISPR RNA (crRNA), or ribozymes, preferably mRNA, more preferably modified mRNA.